Insulin independence for LCT
Tuesday, 07 April, 2009
New Zealand’s Living Cell Technologies has reported that a patient with type 1 diabetes is currently insulin independent following treatments in an early stage trial.
LCT is running the safety and dosing trial in Moscow. Seven patients have received Diabecell implants at a low or medium dose.
Diabecell is a microencapsulated product containing insulin-producing porcine islet cells. In the female patient, live porcine cells in their capsules have been found in the abdomen and porcine insulin was detected in her blood.
The 37-year-old had been on daily insulin injections for 15 years. She is now maintaining good blood glucose control without injections, LCT said.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
